Higher levels of beta 2 microglobulin were independently associated with an increased risk of major adverse cardiovascular events compared with the lowest quartile (HR 1.88; 95% CI, 1.26 to 2.79; P<0.001).
Cohort (n=1,005)
Do elevated levels of beta 2 microglobulin predict major adverse cardiovascular events in neurologically asymptomatic patients with carotid atherosclerosis?
Beta 2 microglobulin is an independent predictor of major adverse cardiovascular events in patients with asymptomatic carotid atherosclerosis, improving risk stratification beyond traditional baseline risk factors.
Estimación del efecto: HR 1.88 (95% CI 1.26 to 2.79)
valor p: p=<0.001
BACKGROUND AND PURPOSE: Atherosclerosis is a chronic inflammatory disease. Ongoing inflammation is associated with elevated levels of beta 2 microglobulin (B2M). We investigated B2M levels in a large cohort of patients with carotid atherosclerosis for the occurrence of major adverse cardiovascular events. METHODS: One thousand five of 1286 consecutive, neurologically asymptomatic patients with carotid atherosclerosis were followed for a median of 3 years (interquartile range, 2.5 to 3.5) for the occurrence of major adverse cardiovascular events, a composite of myocardial infarction, percutaneous coronary intervention, coronary bypass graft, stroke, and death. RESULTS: We recorded 359 major cardiovascular events in 271 (27%) patients. B2M was significantly associated with the occurrence of major adverse cardiovascular events. With increasing quartiles of B2M, the adjusted hazard ratios were 1.19 (95% CI, 0.81 to 1.73), 1.51 (95% CI, 1.05 to 2.18), and 1.88 (95% CI, 1.26 to 2.79) compared with the lowest quartile, respectively (P<0.001). Adjusted hazard ratios for the occurrence of death, myocardial infarction, and stroke for increasing quartiles of B2M were 1.25 (95% CI, 0.92 to 1.70), 1.52 (95% CI, 1.12 to 2.06), and 1.62 (95% CI, 1.16 to 2.67) compared with the lowest quartile, respectively (P<0.001). Through statistical estimation of improvement in risk stratification, addition of B2M to baseline risk factors improved the risk stratification for major cardiovascular events, at least as much as high-sensitivity C-reactive protein or even better. CONCLUSIONS: B2M was independently and significantly associated with adverse cardiovascular outcome in patients with prevalent asymptomatic carotid atherosclerosis.
Amighi et al. (Fri,) conducted a cohort in Asymptomatic carotid atherosclerosis (n=1,005). Beta 2 microglobulin (B2M) levels vs. Lowest quartile of B2M was evaluated on Major adverse cardiovascular events (composite of myocardial infarction, percutaneous coronary intervention, coronary bypass graft, stroke, and death) (HR 1.88, 95% CI 1.26 to 2.79, p=<0.001). Higher levels of beta 2 microglobulin were independently associated with an increased risk of major adverse cardiovascular events compared with the lowest quartile (HR 1.88; 95% CI, 1.26 to 2.79; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: